Genentech Avastin Early Sales Data Suggest Broad Use In Colorectal Cancer
Genentech is receiving public reimbursement for use of Avastin in both first-line and relapsed/refractory metastatic colorectal cancer, the company told investors April 8
Genentech is receiving public reimbursement for use of Avastin in both first-line and relapsed/refractory metastatic colorectal cancer, the company told investors April 8